Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 5:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Viral Suppression of HIV Infection Clear all
Completed Not applicable Interventional

Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected With HIV

NCT00006441
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/Zidovudine, Nelfinavir mesylate, Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
2
States / cities
Birmingham, Alabama • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2015 · Synced Jun 11, 2026, 5:25 AM EDT
Completed Phase 3 Interventional

Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen

NCT00002429
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/Zidovudine, Nelfinavir mesylate, Stavudine, Didanosine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 3, 2011 · Synced Jun 11, 2026, 5:25 AM EDT
Withdrawn Phase 3 Interventional

Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women

NCT00984152
View directory record Official record
Conditions
HIV-1 Infections
Interventions
TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily, TDF/FTC + Efavirenz (Atripla) Once-Daily
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 60 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Jun 11, 2026, 5:25 AM EDT
Completed Phase 3 Interventional

Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir

NCT00120393
View directory record Official record
Conditions
HIV Infections
Interventions
atazanavir/ritonavir +2 NRTIs (immediate Switch Group), LPV/r +2 NRTIs (Delayed/optional Switch Group)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
12
States / cities
Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2010 · Synced Jun 11, 2026, 5:25 AM EDT
Completed No phase listed Observational

HIV Jail POC-AgAB Testings

NCT04296331
View directory record Official record
Conditions
HIV/AIDS
Interventions
POC, Ag/Ab, POC + Ag/Ab
Diagnostic Test
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
6,613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced Jun 11, 2026, 5:25 AM EDT
Completed Phase 2 Interventional Results available

Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir

NCT00976404
View directory record Official record
Conditions
HIV Infection
Interventions
DNA + HIV-rAd5 vaccine, ART intensification (raltegravir), ART intensification (maraviroc)
Biological · Drug
Lead sponsor
Robert L. Murphy
Other
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Jun 11, 2026, 5:25 AM EDT
Completed No phase listed Observational

Retrospective Review of DTG/3TC Versus BIC/F/TAF Across a Multi Clinic Infectious Disease Organization in Southeast United States

NCT06393387
View directory record Official record
Conditions
Hiv, HIV-1-infection, HIV Infections
Interventions
DTG/3TC versus BIC/F/TAF
Drug
Lead sponsor
Midway Specialty Care Center
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Jun 11, 2026, 5:25 AM EDT
Terminated Not applicable Interventional Results available

Pilot Study of Effect of Kaletra on CD4 Response in HIV Positive (+) Patients With Viral Suppression KIMBO Study

NCT00344487
View directory record Official record
Conditions
HIV
Interventions
Lopinavir/Ritonavir
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 23, 2022 · Synced Jun 11, 2026, 5:25 AM EDT
Completed Phase 4 Interventional Results available

FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment

NCT00414635
View directory record Official record
Conditions
HIV Infections
Interventions
Intermitent Dosing
Drug
Lead sponsor
Community Research Initiative of New England
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Miami, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Jun 11, 2026, 5:25 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

NCT02938520
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), ABC/DTG/3TC STR - Tablet, DTG Tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
9
States / cities
Long Beach, California • Los Angeles, California • Augusta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jun 11, 2026, 5:25 AM EDT
Completed No phase listed Observational

Immune and Viral Status of HIV-Infected Patients After Stopping Combination Antiretroviral Therapy

NCT00001899
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Jun 11, 2026, 5:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

NOLA GEM: Feasibility and Acceptability of an MHealth Intervention for Violence-affected PLWH

NCT05784714
View directory record Official record
Conditions
HIV, Mental Health, Substance Use
Interventions
NOLA GEM
Behavioral
Lead sponsor
Tulane University
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
4
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Jun 11, 2026, 5:25 AM EDT
Completed Phase 2 Interventional

A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients

NCT00000912
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Efavirenz, Levocarnitine, Adefovir dipivoxil, Saquinavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
44
States / cities
Los Angeles, California • Menlo Park, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Jun 11, 2026, 5:25 AM EDT
Completed Phase 1 Interventional

Combination Drug Treatment of Pediatric HIV Infection

NCT00001818
View directory record Official record
Conditions
HIV Infection
Interventions
Hydroxyurea
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 11, 2026, 5:25 AM EDT
Enrolling by invitation Not applicable Interventional

Clinic-level Implementation of mHealth to Improve HIV Viral Suppression for Patients With Substance Use Disorders

NCT06109571
View directory record Official record
Conditions
HIV Infections, Substance Use Disorders
Interventions
Connections App
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Denver, Colorado • Kansas City, Missouri • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Jun 11, 2026, 5:25 AM EDT
Completed Not applicable Interventional

Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome

NCT00000627
View directory record Official record
Conditions
HIV Infections, Histoplasmosis
Interventions
Fluconazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Jun 11, 2026, 5:25 AM EDT
Completed Phase 4 Interventional Results available

CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery

NCT00925756
View directory record Official record
Conditions
HIV Infections
Interventions
Maraviroc
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
3
States / cities
Los Angeles, California • San Diego, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Jun 11, 2026, 5:25 AM EDT
Completed Phase 1 Interventional

Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals

NCT00428519
View directory record Official record
Conditions
HIV Infections
Interventions
Placebo, Aprepitant
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Jun 11, 2026, 5:25 AM EDT
Not listed Phase 4 Interventional

Raltegravir and Atazanavir Replacing Current Suppressive Treatment Because of Side Effects in Current Treatment

NCT00751153
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir and Atazanavir
Drug
Lead sponsor
Peter J. Ruane, M.D., Inc.
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2008 · Synced Jun 11, 2026, 5:25 AM EDT
Completed Not applicable Interventional

Technology Based Community Health Nursing to Improve Combination Anti-Retroviral Therapy (cART) Adherence and Virologic Suppression in Youth Living With HIV

NCT03600103
View directory record Official record
Conditions
HIV Infections, Adherence, Medication
Interventions
Tech2Check
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years to 25 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Jacksonville, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Jun 11, 2026, 5:25 AM EDT
Completed Not applicable Interventional

Scale-up of an Internet-Delivered Study for HIV+ Men

NCT02023580
View directory record Official record
Conditions
HIV
Interventions
Video treatments
Behavioral
Lead sponsor
Public Health Solutions
Other
Eligibility
18 Years and older · Male only
Enrollment
1,197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Jun 11, 2026, 5:25 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Case Management Dyad

NCT06162897
View directory record Official record
Conditions
HIV, Pre-exposure Prophylaxis, Case Management
Interventions
Dyadic Case Management
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Jun 11, 2026, 5:25 AM EDT
Completed Phase 2 Interventional

A Study of Itraconazole in the Treatment and Prevention of Histoplasmosis, a Fungal Infection, in Patients With AIDS

NCT00000975
View directory record Official record
Conditions
HIV Infections, Histoplasmosis
Interventions
Itraconazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
12
States / cities
Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jun 11, 2026, 5:25 AM EDT
Completed No phase listed Observational

Evolution of L74V or K65R Mutations in VIremic Subjects on Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) (EVITA)

NCT00312169
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
Orlando Immunology Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
11
States / cities
Fresno, California • Los Angelos, California • Tarzana, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 21, 2008 · Synced Jun 11, 2026, 5:25 AM EDT